Advertisement

Pharmaceutisch Weekblad

, Volume 11, Issue 4, pp 106–108 | Cite as

Pulmonary defence mechanisms: Damage and repair

Opportunities for intervention
  • Evert F. Weltevreden
Therapeutic Interventions in Lower Respiratory Tract Infections

Abstract

In this article pulmonary defence mechanisms and factors causing (progressive) tissue damage in some common settings of lower respiratory tract infections are dealt with. Opportunities for intervention are different, considering the proper cause. Passive immunization is appropriate in case of immune deficiency and active immunization applies to a series of clinical conditions in which the immune system for the greater part is intact but other defence mechanisms are impaired. Besides antibiotic treatment, anti-inflammatory therapy is considered beneficial, anticipating progressive tissue damage.

Keywords

Defence mechanisms Drug therapy Infection Inflammation Lung 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Van der Baan S, Veerman AJP, Weltevreden EF, Feenstr L. Kartagener's syndrome: clinical symptoms and laboratory studies. Eur J Dis 1983;64(Suppl 127):91–5.Google Scholar
  2. 2.
    Green GM, Jakab GJ, Low RB, Davis GS. Defence mechanisms of the respiratory membrane. Am Rev Respir Dis 1977;115:479–514.PubMedGoogle Scholar
  3. 3.
    Bice DE. Induction of antibody responses after localized immunization. Bull Fijnvl Longafw 1987;12:47–53.Google Scholar
  4. 4.
    Colby ThV, Chung AC. Patterns of pulmonary fibrosis. Pathol Ann 1986;21:277–309.Google Scholar
  5. 5.
    Willems LNA. Antileukoprotease in the human lung. A morphologic study [Dissertation]. Leiden: Leiden University, 1988.Google Scholar
  6. 6.
    Corrin B. Epithelial and endothelial cells in alveolar damage and repair. Bull Fijnvl Longafw 1987;12:64–7.Google Scholar
  7. 7.
    Basset F, Soler P. Connective tissue cells in pulmonary alveolar damage repair. Bull Fijnvl Longafw 1987;12:68–72.Google Scholar
  8. 8.
    Döring G, Albus A, Hóiby N. Immunologic aspects of cystic fibrosis. Chest 1988;94(Suppl 2):109s.Google Scholar
  9. 9.
    Schein RM, Bergman R, Marcial EH, et al. Complement activation and corticosteroid therapy in the development of the adult respiratory distress syndrome. Chest 1987;91:850–4.PubMedGoogle Scholar
  10. 10.
    Wevers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha-1-proteinase deficiency associated with emphysema. N Engl J Med 1987:147:166–9.Google Scholar
  11. 11.
    Masoro EJ. Biology of aging. Current state of knowledge. Arch Intern Med 1987:147:166–9.PubMedGoogle Scholar
  12. 12.
    Busse WW. The contribution of viral respiratory infections to the pathogenesis of airway hyperreactivity. Chest 1988:93:1076–81.PubMedGoogle Scholar
  13. 13.
    Wilson R, Roberts D, Cole P. Effect of bacterial products on human ciliary functionin vitro. Thorax 1985;40:125–31.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • Evert F. Weltevreden
    • 1
  1. 1.Pathological InstituteCL Deventerthe Netherlands

Personalised recommendations